Recently, the World Health Organisation (WHO) announced the prequalification of a second vaccine for dengue TAK-003.

TAK-003 Vaccine

  • This vaccine has been made by the Japanese drug maker Takeda Pharmaceuticals. 
  • It is a live-attenuated vaccine containing weakened versions of the four serotypes of the virus that cause dengue.
  • This vaccine helps the body to build immunity without causing the disease.
  • Only two dengue vaccines have been prequalified to date.
  • The WHO had previously prequalified the CYD-TDV vaccine against dengue, developed by Sanofi Pasteur.
  • This vaccine can be given to children aged 6 to 16 years in areas with high dengue prevalence and transmission rate.
  • According to the WHO, the vaccine should be given in a 2-dose schedule with a 3-month interval between doses.
  • Countries approved the vaccine: The UK, Brazil, Argentina, Indonesia and Thailand. 

World Health Organisation (WHO) prequalification

  • It means that the health agency has assessed and approved the vaccine for quality, safety, and efficacy.
  • It ensures that the vaccine meets international standards and can be used globally, particularly in low- and middle-income countries.
  • Prequalification allows the vaccine to be included in procurement by UN agencies and other global health organisations.

About Dengue 

  • Dengue is a vector-borne infectious disease transmitted through the bites of infected female mosquitoes, primarily by Aedes aegypti (Aedes aegypti) and Aedes albopictus (Aedes albopictus) mosquitoes
  • Dengue viruses belong to the genus Flavivirus within the family Flaviviridae. Flaviviruses are lipid-enveloped, single-stranded RNA viruses.
  • It is estimated that there are over 100-400 million cases of dengue worldwide each year.
  • The largest number of dengue cases reported was in 2023 with the WHO Region of the Americas reporting 4.5 million cases and 2300 deaths.

Also Read:

Affordable Sensor Developed for Detecting Lead Contamination